Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance

MYRIAD GENETICS INC

2023-FY EPS reported -$3.18 revenue$753,200,000

Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).
Q4 GAAP EPS $(0.36); adjusted EPS $0.04, first positive adjusted EPS in recent quarters.
Q4 Hereditary Cancer revenue $88.9M (+5% YoY); Prenatal $40.0M (+37% YoY); GeneSight $35.6M (+11% YoY).
FY2024 revenue guidance raised to $820-840M (9-11% growth); adjusted EPS guidance $0.00-$0.05.
Acquired select assets from Intermountain Precision Genomics in Feb 2024, including Precise Tumor and Liquid tests.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MYRIAD GENETICS INC reported the three months ended December 31, 2023 results: revenue $197 million, EPS $(0.36). Guidance raised.

Period: the three months ended December 31, 2023
Revenue: $197 million
EPS: $(0.36)
Guidance: raised
Result: reported results

Exact text from the filing

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.